In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $63.13, with a +1.94% movement compared to the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.19%. Meanwhile, the Dow experienced a drop of 0.7%, and the technology-dominated Nasdaq saw an increase of 0.04%.Shares of the company have appreciated by 0.85% over the course of the past month, outperforming the Medical sector's loss of 1.58% and lagging the S&P 500's gain of 1.95%.Analysts and investors alike w ...

Hardly for the first time, a pundit following the company waxed bullish on its future.Viking Therapeutics (VKTX 1.94%), a biotech stock that has rocketed to prominence thanks to one of its investigational drugs, gave investors more reason to like it on Wednesday. The company's share price rose by almost 2% following an analyst's bullish new research note; that increase stood in positive contrast to the 0.2% decline of the S&P 500 index.Weight loss drug in the spotlightThe author of that note was Oppenheimer ...

Like some other analysts, I believe that, due to the strong efficacy of Viking Therapeutics, Inc. (NASDAQ: VKTX ) weight-loss drug, VK2735, the company will probably eventually be acquired by a large pharmaceutical firm. But I think (after conducting extensiveAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am ...

Viking Therapeutics TodayVKTXViking Therapeutics$64.45 +1.51 (+2.40%) 52-Week Range$8.28▼$99.41Price Target$108.60Add to WatchlistViking Therapeutics Inc. NASDAQ: VKTX, a clinical-stage biotechnology company with a market cap approaching $7 billion, is turning heads in 2024. Year to date, the stock has surged an impressive 238%, and its rise over the past 12 months has been even more dramatic, with shares climbing 326%.For a mid-cap biotech, these kinds of gains significantly outpace both the broader market ...

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $67.10, demonstrating a +0.55% swing from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.13% for the day. On the other hand, the Dow registered a gain of 0.55%, and the technology-centric Nasdaq decreased by 0.52%.Shares of the company witnessed a gain of 17.67% over the previous month, beating the performance of the Medical sector with its gain of 3.34% and the S&P 500's gain of 3.67%.The u ...

The company is looking especially good after some bad news coming from a rival.For the second day in a row, a pundit's take on Viking Therapeutics (VKTX 3.25%) helped push the biotech's share price higher. It was this rather than inherent news from the company that added more than 3% to said price, a gain that handily beat the S&P 500 index's 0.8% increase. Thumbs-up from bullish punditThe latest analyst to weigh in on Viking's prospects was Morgan Stanley's Michael Ulz, who early Thursday morning published ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Viking Therapeutics, Inc. (VKTX) .Viking Therapeutics currently h ...

The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug.Viking Therapeutics (VKTX 11.31%) stormed the stock market on Wednesday. Shares of the up-and-coming biotech rose by more than 11% not on any proprietary news from the company, but on an analyst's initiation of coverage. That performance was more than enough to top the trajectory of the bellwether S&P 500 index, which rose by slightly over 1% on the day.32% upside potential, analyst bel ...

Key TakeawaysShares of Viking Therapeutics surged Wednesday after J.P. Morgan analysts initiated coverage of the drugmaker at "overweight" and shared an optimistic view.Viking is developing weight-loss drugs that have boosted its stock after positive trial results since the start of this year, and analysts say it might happen again.In the long term, analysts predict that Viking's anticipated oral weight-loss drug could claim about 10% of the market in the years following its projected 2030 release. Viking T ...

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc VKTX with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65.At the core of this bullish outlook is Viking’s obesity drug candidate, oral-2735, which could be a significant player in the rapidly expanding GLP-1 market.Oral-2735 Could Be A Game ChangerJPMorgan highlights oral-2735's potential as a highly competitive treatment in the GLP-1 market, partic ...